文献速递免疫规划

AS03佐剂H7N1疫苗在65岁及以上成人中的免疫原性与安全性:一项II期、观察者盲法、随机对照试验

Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65years of age and older: A phase II, observer-blind, randomized, controlled trial.
PubMed 文献 · Vaccine · 2017-03-13

这项II期观察者盲法随机对照试验纳入360名≥65岁健康成人,比较4种AS03佐剂H7N1疫苗配方(3.75μg或7.5μg血凝素分别佐以AS03A或AS03B)与生理盐水安慰剂,按2剂程序接种。接种2剂后疫苗组免疫原性可接受,最常见征集性症状为注射部位疼痛,未发现与疫苗因果相关的严重不良事件;抗体指标在6个月和12个月时下降。

要点

  • 在≥65岁成人中,AS03佐剂H7N1疫苗接种2剂后具有免疫原性,安全性可接受。
  • 第42天疫苗组HI抗体血清保护率69.6%-88.7%,血清转化率69.6%-88.5%。
  • 最常见征集性症状为注射部位疼痛,疫苗受种者中发生率为41.7%-65.0%。

核心结论

  • 在≥65岁成人中,AS03佐剂H7N1疫苗在接种2剂后具有免疫原性,且安全性可接受。

研究设计与样本

  • II期、观察者盲法、随机对照试验(ClinicalTrials.gov:NCT01949090),360名≥65岁健康状况稳定的成人接受4种AS03佐剂A/mallard/Netherlands/12/2000裂解病毒疫苗配方之一(3.75μg或7.5μg血凝素分别佐以AS03A或AS03B)或生理盐水安慰剂,按2剂程序接种。
  • 免疫原性在意向性方案队列中采用血凝抑制(HI)和微量中和(MN)试验评估,第2剂后21天及第6个月各332人,第12个月309人(仅HI试验);安全性评估至第12个月,覆盖所有接受≥1剂者(360人)。

主要发现

  • 第42天(第2剂后21天)疫苗组H7N1 HI抗体血清保护率为69.6%-88.7%,血清转化率为69.6%-88.5%,平均几何增长为11.0-18.9,HI几何平均滴度为55.0-104.8。
  • 上述HI参数在第6个月和第12个月下降。
  • 第42天疫苗组微量中和几何平均滴度为46.2-74.7,疫苗应答率(MN滴度≥4倍升高者比例)为46.4%-81.5%。
  • 对交叉反应性H7N9株,第42天HI几何平均滴度为64.3-201.3,血清保护率为78.6%-96.3%,血清转化率为79.3%-96.3%,平均几何增长为14.1-37.7;MN几何平均滴度为44.0-85.6,疫苗应答率为46.4%-85.2%。
  • 最常见的征集性症状为注射部位疼痛,疫苗受种者中发生率为41.7%-65.0%;共40名参与者报告67例严重不良事件,均被认为与疫苗接种无因果关系。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: H7 influenza strains can cause severe and often fatal human infections, especially in the elderly. This phase II, observer-blind, randomized trial (www.ClinicalTrials.gov: NCT01949090) assessed the immunogenicity and safety of a novel AS03-adjuvanted H7N1 vaccine that may serve as a model H7-subtype vaccine. METHODS: 360 adults ≥65years of age in stable health received either 1 of 4 adjuvanted A/mallard/Netherlands/12/2000 split virion vaccine formulations (3.75μg or 7.5μg hemagglutinin adjuvanted with either AS03A or AS03B) or saline placebo, given as a 2-dose series. Immunogenicity was assessed using hemagglutination-inhibition (HI) and microneutralization (MN) assays for the per-protocol cohort, comprising 332 participants at 21days post-each dose, 332 at month 6, and 309 at month 12 (HI assay only). Safety was assessed up to month 12 for all participants who had received ≥1 dose (360 participants). RESULTS: For H7N1 HI antibody assessment at day 42 (21days post-dose 2), seroprotection rates (SPR) in the vaccinated groups were 69.6%-88.7%, seroconversion rates (SCR) 69.6%-88.5%, mean geometric increase (MGI) 11.0-18.9, and HI geometric mean titers (GMTs) 55.0-104.8. These parameters declined by month 6 and month 12. Microneutralization GMTs were 46.2-74.7 in the vaccinated groups at day 42, while vaccine response rate (VRR; proportion with ≥4-fold increase in MN titer) was 46.4%-81.5%. For the cross-reactive H7N9 strain, at day 42, HI GMT were 64.3-201.3, SPR 78.6%-96.3%, SCR 79.3%-96.3%, and MGI 14.1-37.7; MN GMTs were 44.0-85.6, and VRR 46.4-85.2%. The most frequent solicited symptom was injection site pain (41.7%-65.0% of vaccine recipients). In total, 40 participants reported 67 serious adverse events; none were considered causally related to vaccination. CONCLUSIONS: In adults aged ≥65years, the adjuvanted H7N1 vaccine was immunogenic after 2 doses, and had an acceptable safety profile. www.ClinicalTrials.gov: NCT01949090.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Madan A, Ferguson M, Rheault P, et al. Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65years of age and older: A phase II, observer-blind, randomized, controlled trial. Vaccine. 2017. PMID: 28302407. doi:10.1016/j.vaccine.2017.02.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。